Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lead (212Pb) bamzireotide navoxetan
- Development stage
- Unknown
- Lead developer
- Perspective Therapeutics
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals, Beta-minus Emitters → Radiopharmaceuticals, Peptides
- Administration
- Intravenous
01
Overview
Lead (212Pb) bamzireotide navoxetan (VMT-alpha-NET) is an investigational, SSTR2-targeted alpha-particle radiopharmaceutical therapy developed by Perspective Therapeutics (originally Viewpoint Molecular Targeting). The drug consists of a somatostatin analog peptide (PSC-PEG2-TOC) that selectively binds to somatostatin receptor subtype 2 (SSTR2), which is highly overexpressed on various neuroendocrine and solid tumors. The peptide is conjugated via a proprietary lead-specific chelator to the alpha-emitting radioisotope lead-212 (212Pb). Upon binding to SSTR2, the radioligand is internalized, delivering high-energy, short-range alpha radiation directly to the tumor cells, causing lethal double-strand DNA breaks while minimizing damage to surrounding healthy tissues. VMT-alpha-NET is currently in Phase 1/2 clinical development for the treatment of SSTR2-expressing tumors, including gastroenteropancreatic neuroendocrine tumors (GEP-NETs), pheochromocytomas, paragangliomas, meningiomas, small cell lung cancer, renal cell carcinoma, and olfactory neuroblastoma.
- Other names
- Lead (212Pb) Bamzireotide NavoxetanLead Bamzireotide Navoxetan Pb-212bamzireotide navoxetan
02
Targets
SSTR2 (Somatostatin receptor type 2)
Beyond the preview
Go deeper on lead (212Pb) bamzireotide navoxetan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lead (212Pb) bamzireotide navoxetan.